0DL Stock Overview
Designs, manufactures, and distributes rapid diagnostic tests in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biosynex SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.10 |
| 52 Week High | €9.85 |
| 52 Week Low | €2.80 |
| Beta | -2.28 |
| 11 Month Change | -15.29% |
| 3 Month Change | 40.65% |
| 1 Year Change | -57.82% |
| 33 Year Change | -78.59% |
| 5 Year Change | n/a |
| Change since IPO | -80.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0DL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.0% | 12.4% | 3.1% |
| 1Y | -57.8% | 9.5% | 13.3% |
Return vs Industry: 0DL underperformed the German Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: 0DL underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 0DL volatility | |
|---|---|
| 0DL Average Weekly Movement | 14.9% |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0DL's share price has been volatile over the past 3 months.
Volatility Over Time: 0DL's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 569 | Larry Abensur | www.biosynex.com |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products.
Biosynex SA Fundamentals Summary
| 0DL fundamental statistics | |
|---|---|
| Market cap | €44.71m |
| Earnings (TTM) | -€36.95m |
| Revenue (TTM) | €92.98m |
0.5x
P/S Ratio-1.2x
P/E RatioIs 0DL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0DL income statement (TTM) | |
|---|---|
| Revenue | €92.98m |
| Cost of Revenue | €43.85m |
| Gross Profit | €49.13m |
| Other Expenses | €86.08m |
| Earnings | -€36.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.43 |
| Gross Margin | 52.84% |
| Net Profit Margin | -39.74% |
| Debt/Equity Ratio | 51.6% |
How did 0DL perform over the long term?
See historical performance and comparison